Literature DB >> 19238376

Modulation of aggregate size- and shape-distributions of the amyloid-beta peptide by a designed beta-sheet breaker.

Luitgard Nagel-Steger1, Borries Demeler, Wolfgang Meyer-Zaika, Katrin Hochdörffer, Thomas Schrader, Dieter Willbold.   

Abstract

A peptide with 42 amino acid residues (Abeta42) plays a key role in the pathogenesis of the Alzheimer's disease. It is highly prone to self aggregation leading to the formation of fibrils which are deposited in amyloid plaques in the brain of diseased individuals. In our study we established a method to analyze the aggregation behavior of the Abeta peptide with a combination of sedimentation velocity centrifugation and enhanced data evaluation software as implemented in the software package UltraScan. Important information which becomes accessible by this methodology is the s-value distribution and concomitantly also the shape-distribution of the Abeta peptide aggregates generated by self-association. With this method we characterized the aggregation modifying effect of a designed beta-sheet breaker molecule. This compound is built from three head-to-tail connected aminopyrazole moieties and represents a derivative of the already described Tripyrazole. By addition of this compound to a solution of the Abeta42 peptide the maximum of the s-value distribution was clearly shifted to smaller s-values as compared to solutions where only the vehicle DMSO was added. This shift to smaller s-values was stable for at least 7 days. The information about size- and shape-distributions present in aggregated Abeta42 solutions was confirmed by transmission electron microscopy and by measurement of amyloid formation by thioflavin T fluorescence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19238376     DOI: 10.1007/s00249-009-0416-2

Source DB:  PubMed          Journal:  Eur Biophys J        ISSN: 0175-7571            Impact factor:   1.733


  20 in total

1.  Quantification of beta-sheet amyloid fibril structures with thioflavin T.

Authors:  H LeVine
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

2.  An ultrastructural study of amyloid intermediates in A beta1-42 fibrillogenesis.

Authors:  M Nybo; S E Svehag; E Holm Nielsen
Journal:  Scand J Immunol       Date:  1999-03       Impact factor: 3.487

3.  Sedimentation velocity analysis of highly heterogeneous systems.

Authors:  Borries Demeler; Kensal E van Holde
Journal:  Anal Biochem       Date:  2004-12-15       Impact factor: 3.365

4.  Solution state characterization of amyloid beta-derived diffusible ligands.

Authors:  Robert W Hepler; Karen M Grimm; Deborah D Nahas; Robert Breese; Elizabeth Chen Dodson; Paul Acton; Paul M Keller; Mark Yeager; Hui Wang; Paul Shughrue; Gene Kinney; Joseph G Joyce
Journal:  Biochemistry       Date:  2006-12-06       Impact factor: 3.162

Review 5.  Novel strategies for Alzheimer's disease treatment.

Authors:  Brian Spencer; Edward Rockenstein; Leslie Crews; Robert Marr; Eliezer Masliah
Journal:  Expert Opin Biol Ther       Date:  2007-12       Impact factor: 4.388

6.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

7.  Evidence of the existence of micelles in the fibrillogenesis of beta-amyloid peptide.

Authors:  Raimon Sabaté; Joan Estelrich
Journal:  J Phys Chem B       Date:  2005-06-02       Impact factor: 2.991

8.  An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments.

Authors:  Y Fezoui; D M Hartley; J D Harper; R Khurana; D M Walsh; M M Condron; D J Selkoe; P T Lansbury; A L Fink; D B Teplow
Journal:  Amyloid       Date:  2000-09       Impact factor: 7.141

9.  New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease.

Authors:  Hilal A Lashuel; Dean M Hartley; David Balakhaneh; Aneel Aggarwal; Saul Teichberg; David J E Callaway
Journal:  J Biol Chem       Date:  2002-08-06       Impact factor: 5.157

Review 10.  A beta oligomers - a decade of discovery.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurochem       Date:  2007-02-05       Impact factor: 5.372

View more
  10 in total

1.  Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice.

Authors:  Susanne Aileen Funke; Thomas van Groen; Inga Kadish; Dirk Bartnik; Luitgard Nagel-Steger; Oleksandr Brener; Torsten Sehl; Renu Batra-Safferling; Christine Moriscot; Guy Schoehn; Anselm H C Horn; Andreas Müller-Schiffmann; Carsten Korth; Heinrich Sticht; Dieter Willbold
Journal:  ACS Chem Neurosci       Date:  2010-08-02       Impact factor: 4.418

2.  Improved optical slicing by stimulated emission depletion light sheet microscopy.

Authors:  José Martínez Hernández; Alain Buisson; Irène Wang; Jean-Claude Vial
Journal:  Biomed Opt Express       Date:  2020-01-08       Impact factor: 3.732

3.  The biofilm adhesion protein Aap from Staphylococcus epidermidis forms zinc-dependent amyloid fibers.

Authors:  Alexander E Yarawsky; Stefanie L Johns; Peter Schuck; Andrew B Herr
Journal:  J Biol Chem       Date:  2020-02-26       Impact factor: 5.157

4.  The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?

Authors:  Kerensa Broersen; Frederic Rousseau; Joost Schymkowitz
Journal:  Alzheimers Res Ther       Date:  2010-07-14       Impact factor: 6.982

Review 5.  Peptides for therapy and diagnosis of Alzheimer's disease.

Authors:  Susanne Aileen Funke; Dieter Willbold
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 6.  Unraveling the early events of amyloid-β protein (Aβ) aggregation: techniques for the determination of Aβ aggregate size.

Authors:  N Elizabeth Pryor; Melissa A Moss; Christa N Hestekin
Journal:  Int J Mol Sci       Date:  2012-03-07       Impact factor: 6.208

7.  Amyloid β Oligomeric Species Present in the Lag Phase of Amyloid Formation.

Authors:  Martin Wolff; Dmitry Unuchek; Bo Zhang; Valentin Gordeliy; Dieter Willbold; Luitgard Nagel-Steger
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

8.  Aβ42 pentamers/hexamers are the smallest detectable oligomers in solution.

Authors:  Martin Wolff; Bo Zhang-Haagen; Christina Decker; Bogdan Barz; Mario Schneider; Ralf Biehl; Aurel Radulescu; Birgit Strodel; Dieter Willbold; Luitgard Nagel-Steger
Journal:  Sci Rep       Date:  2017-05-30       Impact factor: 4.379

9.  Structure and Enzymatic Activity of an Intellectual Disability-Associated Ornithine Decarboxylase Variant, G84R.

Authors:  X Edward Zhou; Chad R Schultz; Kelly Suino Powell; Amy Henrickson; Jared Lamp; Joseph S Brunzelle; Borries Demeler; Irving E Vega; André S Bachmann; Karsten Melcher
Journal:  ACS Omega       Date:  2022-09-13

10.  Immobilization of homogeneous monomeric, oligomeric and fibrillar Aβ species for reliable SPR measurements.

Authors:  Daniel Frenzel; Julian M Glück; Oleksandr Brener; Filipp Oesterhelt; Luitgard Nagel-Steger; Dieter Willbold
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.